Diabetes, Vol 36, Issue 3 274-283, Copyright © 1987 by American Diabetes Association

ARTICLES

Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics

AD Baron, L Schaeffer, P Shragg and OG Kolterman

Elevated rates of basal hepatic glucose output (bHGO) are significantly correlated with the fasting serum glucose (FSG) level in subjects with non-insulin-dependent diabetes mellitus (NIDDM). This observation suggests that bHGO is a major determinant of the severity of the diabetic state in these subjects. In addition, basal glucagon levels (bGL) are higher in these diabetics than in control subjects, despite the concurrent basal hyperglycemia and hyperinsulinemia, two factors known to suppress glucagon secretion. Although bGL is responsible for sustaining two-thirds of bHGO in normal humans, its role in sustaining elevated rates of bHGO in NIDDM has not been previously defined. To this end, we have studied 13 normal and 10 NIDDM subjects; mean FSG levels were 90 +/- 2 and 262 +/- 21 mg/dl, respectively (P less than .001). The mean fasting serum insulin and glucagon levels were higher in the diabetics than in the controls: 17 +/- 2 vs. 9 +/- 1 microU/ml (P less than .01) and 208 +/- 37 vs. 104 +/- 15 pg/ml (P less than .01), respectively. On separate days, HGO was assessed isotopically (with 3-[3H]glucose) in the basal state and during infusion of somatostatin (SRIF) (600 micrograms/h) alone and in conjunction with replacement infusions of glucose and insulin. The results demonstrate that bHGO is higher in diabetics than in controls (145 +/- 12 vs. 89 +/- 3 mg X m-2 X min-1, P less than .01); during infusion of SRIF alone, HGO was suppressed by 25% (P less than .05) and 34% (P less than .05) of the basal value in controls and diabetics, respectively; when the studies were repeated with glucose levels held constant at or near the FSG level by the glucose-clamp technique, the pattern and degree of HGO suppression was similar to that obtained by infusion of SRIF alone; during isolated glucagon deficiency (SRIF + insulin, 5 mU X m-2 min-1, with serum glucose maintained at basal level), HGO was suppressed by 71 +/- 8% of the basal value in controls (P less than .001) and by 58 +/- 7% in diabetics (P less than .001); and when isolated glucagon deficiency with similar hyperglycemia was created in control subjects, HGO was suppressed by 87% of the basal value.(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Ravikumar, J. Gerrard, C. Dalla Man, M. J. Firbank, A. Lane, P. T. English, C. Cobelli, and R. Taylor Pioglitazone Decreases Fasting and Postprandial Endogenous Glucose Production in Proportion to Decrease in Hepatic Triglyceride Content Diabetes, September 1, 2008; 57(9): 2288 - 2295. [Abstract] [Full Text] [PDF]

				B. E. Dunning and J. E. Gerich The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications Endocr. Rev., May 1, 2007; 28(3): 253 - 283. [Abstract] [Full Text] [PDF]

				M. Abdul-Ghani and R. A. DeFronzo Fasting Hyperglycemia Impairs Glucose- But Not Insulin-Mediated Suppression of Glucagon Secretion J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1778 - 1784. [Abstract] [Full Text] [PDF]

				T. H Claus, C. Q Pan, J. M Buxton, L. Yang, J. C Reynolds, N. Barucci, M. Burns, A. A Ortiz, S. Roczniak, J. N Livingston, et al. Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes J. Endocrinol., February 1, 2007; 192(2): 371 - 380. [Abstract] [Full Text] [PDF]

				J. Gromada, I. Franklin, and C. B. Wollheim {alpha}-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains Endocr. Rev., February 1, 2007; 28(1): 84 - 116. [Abstract] [Full Text] [PDF]

				H. Sorensen, M. S. Winzell, C. L. Brand, K. Fosgerau, R. W. Gelling, E. Nishimura, and B. Ahren Glucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired {beta}-Cell Function Diabetes, December 1, 2006; 55(12): 3463 - 3469. [Abstract] [Full Text] [PDF]

				D. A. Elder, R. L. Prigeon, R. P. Wadwa, L. M. Dolan, and D. A. D'Alessio {beta}-Cell Function, Insulin Sensitivity, and Glucose Tolerance in Obese Diabetic and Nondiabetic Adolescents and Young Adults J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 185 - 191. [Abstract] [Full Text] [PDF]

				S. A. Qureshi, M. Rios Candelore, D. Xie, X. Yang, L. M. Tota, V. D.-H. Ding, Z. Li, A. Bansal, C. Miller, S. M. Cohen, et al. A Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects Diabetes, December 1, 2004; 53(12): 3267 - 3273. [Abstract] [Full Text] [PDF]

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]

				S. L. Aronoff, K. Berkowitz, B. Shreiner, and L. Want Glucose Metabolism and Regulation: Beyond Insulin and Glucagon Diabetes Spectr, July 1, 2004; 17(3): 183 - 190. [Abstract] [Full Text] [PDF]

				H. Bays, L. Mandarino, and R. A. DeFronzo Role of the Adipocyte, Free Fatty Acids, and Ectopic Fat in Pathogenesis of Type 2 Diabetes Mellitus: Peroxisomal Proliferator-Activated Receptor Agonists Provide a Rational Therapeutic Approach J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 463 - 478. [Full Text] [PDF]

				O. G. Kolterman, J. B. Buse, M. S. Fineman, E. Gaines, S. Heintz, T. A. Bicsak, K. Taylor, D. Kim, M. Aisporna, Y. Wang, et al. Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes J. Clin. Endocrinol. Metab., July 1, 2003; 88(7): 3082 - 3089. [Abstract] [Full Text] [PDF]

				S. E. Greenway, F. L. Greenway III, and S. Klein Effects of Obesity Surgery on Non-Insulin-Dependent Diabetes Mellitus Arch Surg, October 1, 2002; 137(10): 1109 - 1117. [Abstract] [Full Text] [PDF]

				P. Singhal, A. Caumo, P. E. Carey, C. Cobelli, and R. Taylor Regulation of endogenous glucose production after a mixed meal in type 2 diabetes Am J Physiol Endocrinol Metab, August 1, 2002; 283(2): E275 - E283. [Abstract] [Full Text] [PDF]

				R. A. Velliquette, R. J. Koletsky, and P. Ernsberger Plasma Glucagon and Free Fatty Acid Responses to a Glucose Load in the Obese Spontaneous Hypertensive Rat (SHROB) Model of Metabolic Syndrome X Experimental Biology and Medicine, March 1, 2002; 227(3): 164 - 170. [Abstract] [Full Text] [PDF]

				B. Ahrén, J. J. Holst, and S. Efendic Antidiabetogenic Action of Cholecystokinin-8 in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1043 - 1048. [Abstract] [Full Text]

				B. Ahren, H. Larsson, and J. J. Holst Effects of Glucagon-Like Peptide-1 on Islet Function and Insulin Sensitivity in Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 473 - 478. [Abstract] [Full Text] [PDF]